白细胞介素2基因治疗耐三苯氧胺乳腺癌的实验研究  

Experimental Study of Interleukin 2 Gene Therapy for TAM Resistant Mammary Carcinoma

作　　者：朱森林[1] 苏宁[1] 房广英[1] 张瑞英[1] 张晓明[1] 韩月明[1] 

机构地区：[1]南京铁道医学院病理教研室 [2]广州市沙河人民医院 [3]广东省武警总医院

出　　处：《实用癌症杂志》1998年第2期92-94,共3页The Practical Journal of Cancer

摘　　要：为探讨耐三苯氧胺（Ｔａｍｏｘｉｆｅｎ，ＴＡＭ）乳腺癌细胞因子基因治疗的可行性及效果，在体外将逆转录病毒载体介导的白细胞介素２（ＩＬ－２）基因导入耐ＴＡＭ大鼠乳腺癌细胞株Ｙ２，并进行了动物体内抗肿瘤实验研究。结果显示：同亲代Ｙ２细胞比、基因修饰的ＹＩＬ－２细胞形态和细胞生长特性发生改变。ＰＣＲ显示ＩＬ－２基因成功地整合到ＹＩＬ－２细胞内。ＹＩＬ－２细胞（２．０×１０６个／只）在大鼠右腋皮下失去致瘤性，并阻断等量混合的Ｙ２细胞的致瘤性，但阻断作用随亲代细胞数量的增多而减弱。同样数量无ＩＬ－２基因转移的Ｙ２细胞致瘤率为１００％。结果表明ＹＩＬ－２细胞具有抗肿瘤活性。To investigate the feasibility and effectiveness of interleukin 2 (IL 2) gene therapy for tamoxifen (TAM) resistant mammary carcinoma,the TAM resistant rat mammary carcinoma cell line (Y2 cell) was transfected with human IL 2 gene mediated by retroviral vector LNCX in vitro.The IL 2 gene was identified in the transduced cells by DNA PCR.The antitumor study was performed by animal experiment.The results showed that human IL 2 gene modified tumor cells lost tumorigenesis in rat and got some changes in morphology and biological characteristic.Human IL 2 gene modified cells also inhibited the tumorigenesis of their parent cell line by mixed injection with equal number,but the inhibition was reduced with the increase in number of their parent cells.The results indicated that the IL 2 gene modified cells have antitumor effect.

关 键 词：乳腺癌 基因治疗 白细胞介素2 耐药细胞株 

分 类 号：R737.905[医药卫生—肿瘤]